Harmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo Response
While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.
Harmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo Response Read More »
